First, we determined whether treatment of p75NTR glioma cells (U87p75NTR) using the TNF-α protease inhibitor (TAPI)-2, known to inhibit metalloproteases and ADAMs such as tumor necrosis factor-α converting enzyme (TACE) [36–38] and previously shown to inhibit the proteolytic processing of p75NTR in neurons [26,32,33,39], could inhibit p75NTR processing in glioma cells. This evidence concerns the gene NGFR and central nervous system cancer.